Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Post by Chritterson Aug 30, 2021 4:23pm
111 Views
Post# 33782990

Must Read 2

Must Read 2On June 17, 2021, the Shareholders of the Company approved the transfer and sale to the former shareholders of Talent Biotechs Ltd. (“Talent”) of all assets of the Company’s program developing cannabidiol for the prevention and treatment of graft versus host disease (“GVHD”) in consideration for the release and discharge by the former shareholders of Talent of all existing obligations that the Company and its subsidiaries have to such former shareholders of Talent. According to the agreement, there are certain conditions for the closing: • Former Talent shareholders' satisfaction with the ruling from the Israeli Tax Authorities; • Former Talent shareholders' confirmation that all required reporting have been performed, including reports to the Israeli Registrar regarding the Talent's pledges; • Former Talent shareholders confirmation that all information set forth in section 1 regarding the share capital of Talent is accurate; • The receipt by the Company of the required stock exchange and shareholders’ approval as applicable; As of August 31, 2021, certain conditions have not been fulfilled, therefore, closing of the transaction has not occurred.
<< Previous
Bullboard Posts
Next >>